Intellia Therapeutics (NTLA) EBITDA (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of EBITDA data on file, last reported at -$100.5 million in Q1 2026.

• On a quarterly basis, EBITDA rose 16.78% year-over-year to -$100.5 million in Q1 2026; TTM through Mar 2026 was -$420.7 million, a 22.24% increase from a year earlier, with the FY2025 full-year figure at -$441.0 million, up 17.46% from the prior year.
• EBITDA for Q1 2026 stood at -$100.5 million, down from -$98.7 million in the prior quarter.
• Over the last five years, EBITDA for NTLA reached as high as -$98.3 million in Q2 2022 and fell as low as -$144.8 million in Q3 2024.
• Historically, EBITDA has averaged -$120.5 million across 5 years, with a median of -$114.0 million in 2024.
• Across the five-year window, EBITDA slumped 210.71% in 2022 and rose 27.66% in 2025, its largest moves.
• Year by year, EBITDA stood at -$110.1 million in 2022, then decreased by 27.07% to -$139.9 million in 2023, then gained by 2.46% to -$136.4 million in 2024, then gained by 27.66% to -$98.7 million in 2025, then dropped by 1.85% to -$100.5 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$100.5 million in Q1 2026, -$98.7 million in Q4 2025, and -$111.5 million in Q3 2025.